Generic Name and Formulations:
Ioxilan 300mgI/mL, 350mgI/mL; soln for IV inj; preservative-free.
Indications for OXILAN:
Intraarterial: For cerebral arteriography (300mgI/mL). For coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography (350mgI/mL). IV: For excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body (300mgI/mL and 350mgI/mL).
Individualize. Intraarterial procedures: Left and right coronary: 2–10mL. Left ventricle: 25–50mL. Aortography and selective visceral: see literature. Aortic bifurcation for distal runoff: 45–100mL. Subclavian or femoral artery: 10–40mL. Total dose for procedure should not exceed 250mL. Cerebral arteriography: 8–12mL; total dose for procedure should not exceed 150mL. IV procedures: Excretory urography: 250–390mgI/kg; total dose for procedure should not exceed 100mL. CECT of the head: 100–200mL (300mgI/mL) or 86–172mL (350mgI/mL); total dose for procedure should not exceed 200mL. CECT of body: 50–200mL (300mgI/mL) or 43–172mL (350mgI/mL); total dose for procedure should not exceed 200mL.
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Homocystinuria: avoid. Severe renal impairment. Combined renal and hepatic disease. Combined renal and cardiac disease. CHF. Diabetes. Severe thyrotoxicosis. Myelomatosis. Anuria. Pheochromocytoma. Homozygous sickle cell disease. Immune disorders. Maintain adequate hydration. History of sever cutaneous hypersensitivity reaction; avoid. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Nonionic contrast agent.
Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Headache, fever, hematoma at inj site, chills, angina, hypertension, bradycardia, hypotension, GI upset, dizziness, urticaria, rash; thromboembolic events, hypersensitivity reactions, severe cutaneous reactions (eg, SJS/TEN, AGEP, DRESS).
Single-dose bottles (50mL, 100mL, 150mL, 200mL)—10
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Panel Recommends Earlier Body Weight Monitoring in Use of Mood Stabilizers
- Nondaily Cigarette Use Increasing Among Individuals With Mental Health, Substance Use Disorders
- Cesarean Delivery, Early Childhood Antibiotic Use Not Associated With Risk for ADHD
- Uncertainty as a Form of Violence: Current Immigration Policy and Crisis
- FDA Gets Tough on Juul, Other Electronic Cigarette Makers